Skip to main content

Branded

  • Authorities worry about abuse potential as OxyContin patent expires

    NEW YORK — Purdue Pharma's patent for OxyContin expired Tuesday, opening up the opioid painkiller to generic competition, but authorities have raised concerns about what they call the potential for generic versions to be abused.

  • FDA approves 200-mg strength of Warner Chilcott antibiotic

    DUBLIN — The Food and Drug Administration has approved a new strength of an antibiotic made by Warner Chilcott, the drug maker said.

    Warner Chilcott announced the approval of the 200-mg strength of Doryx (doxycycline hyalite) delayed-release tablets, which the company plans to release in July 2013.

    Doryx delayed-release tablets are already available in the 75-mg, 100-mg and 150-mg strengths.

     

  • FDA approves new labeling for OxyContin

    SILVER SPRING, Md. — The Food and Drug Administration will not approve generic versions of Purdue Pharma's painkiller OxyContin based on earlier versions of the drug that did not include features to thwart abuse, the agency said Tuesday.

    The FDA announced that it approved updated labeling for reformulated OxyContin (oxycodone) extended-release tablets indicating that it has physical and chemical properties designed to deter drug abusers from crushing or dissolving the pills in order to inject or snort them.

  • Mission Pharmacal renews support for March of Dimes event

    SAN ANTONIO — Drug maker Mission Pharmacal has raised nearly $850,000 for the March of Dimes since it began supporting the group, the company said, marking its fourth year of support for the organization.

  • Celgene head elected as PhRMA chairman

    SAN DIEGO — Celgene Corp. chairman and CEO Robert Hugin has been elected as chairman of a pharmaceutical industry trade group.

    The Pharmaceutical Research and Manufacturers of America announced the election of Hugin, as well as Pfizer president and CEO Ian Read as chairman-elect of the PhRMA board of directors and Merck chairman, president and CEO as board treasurer.

    Hugin succeeds Eli Lilly president, chairman and CEO John Lechleiter as chairman, PhRMA said.

     

  • Drug portfolio management teams devote more time, money to niche brands, study finds

    RESEARCH TRIANGLE PARK, N.C. — Drug companies' pharmaceutical portfolio management teams spend most of their time and budgets supporting niche products, according to a new study.

  • Acadia Pharmaceuticals can apply for approval of Parkinson's disease psychosis drug early

    SAN DIEGO — The Food and Drug Administration is granting an expedited application process to a company that has developed a treatment for a condition related to Parkinson's disease, meaning that it can cancel a planned late-stage clinical trial, the company said.

  • Study finds wide disparities in antibiotic prescribing rates between South, Midwest

    NEW YORK — Research has indicated that about half of antibiotic prescriptions are unnecessary, raising concerns about the growth of bacteria resistant to them, but a new study by researchers at the Centers for Disease Control and Prevention also finds that prescriptions are highest in several states in the South and Midwest.

    The study, published Thursday in the New England Journal of Medicine, was based on a database maintained by IMS Health that includes a sample of more than 70% of U.S. prescriptions.

X
This ad will auto-close in 10 seconds